Compare ResMed Inc. (RMD) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Materials Select Sector SPDR Fund — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Materials Select Sector SPDR Fund trades at $51.45. The key difference: ResMed Inc. pays a 1.19% dividend while Materials Select Sector SPDR Fund pays none, and Materials Select Sector SPDR Fund is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| RMD | XLB | |
|---|---|---|
Market Cap | $31.89B | — |
Sector | Health | — |
52-Week High | $283.28 | $53.67 |
52-Week Low | $182.82 | $42.23 |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
XLB trades at $51.95, down 0.93% on the day, with technical indicators showing a bullish overall signal driven by moving averages. The ETF offers broad exposure to the materials sector, which is benefiting from infrastructure spending and AI-related demand. Recent news highlights the sector's potential for earnings growth and defensive characteristics in the current market environment.
The materials sector appears well-positioned for continued growth with strong Q2 earnings momentum and AI infrastructure tailwinds. However, investors face risks from cyclical sector exposure and potential geopolitical supply chain disruptions. Current technical strength suggests near-term upside potential, though valuation metrics remain unavailable for detailed fundamental assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
